Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Table 5

Univariate and multivariate analysis of predicting factors for OS.

Factors	Univariate hazard ratio (95% CI)	value	Multivariate hazard ratio (95% CI)	value
Age
<75	1 (reference)
≥75	1.37 (0.11–1.68)	<0.001	—
Gleason grade group
<4	1 (reference)
≥4	1.82 (1.29–2.59)	<0.0001	—
Initial PSA level, ng/ml
<250	1 (reference)
≥250	1.29 (1.03–1.62)	0.030	—
TTN, month
<9	1 (reference)		1 (reference)
≥9	0.25 (0.20–0.31)	<0.0001	0.24 (0.12–0.48)	<0.0001
Nadir PSA level, ng/ml
<1	1 (reference)		1 (reference)
≥1	3.66 (2.86–4.68)	<0.0001	2.76 (1.98–3.84)	<0.0001
PSARR, % (month)
<10	1 (reference)		1 (reference)
≥10	3.51 (2.73–4.51)	<0.0001	0.53 (0.27–1.04)	0.065
TFNTC, month
<5	1 (reference)		1 (reference)
≥5	0.38 (0.30–0.47)	<0.0001	1.67 (1.18–2.37)	0.004
PSADT, month
<3	1 (reference)		1 (reference)
≥3	0.25 (0.19–0.34)	<0.0001	0.40 (0.28–0.56)	<0.0001
TTC, month
<17	1 (reference)		1 (reference)
≥17	0.20 (0.16–0.25)	<0.0001	0.53 (0.32–0.85)	0.009

TTN: time to PSA nadir, PSARR: PSA reduction rate, TFNTC: time from PSA nadir to CRPC, PSADT: PSA doubling time, and TTC: time from ADT to CRPC.